These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27027783)

  • 21. Enhancing crossover trial design for rare diseases: limiting ineffective exposure and increasing study power by enabling patient choice to escape early.
    Huang B; Giannini EH; Lovell DJ; Ding L; Liu Y; Hashkes PJ
    Contemp Clin Trials; 2014 Jul; 38(2):204-12. PubMed ID: 24833067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early selection in a randomized phase II clinical trial.
    Steinberg SM; Venzon DJ
    Stat Med; 2002 Jun; 21(12):1711-26. PubMed ID: 12111907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes study.
    McClure LA; Szychowski JM; Benavente O; Hart RG; Coffey CS
    Clin Trials; 2016 Oct; 13(5):537-44. PubMed ID: 27094488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal flexible sample size design with robust power.
    Zhang L; Cui L; Yang B
    Stat Med; 2016 Aug; 35(19):3385-96. PubMed ID: 26999385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease.
    Spineli LM; Jenz E; Großhennig A; Koch A
    Orphanet J Rare Dis; 2017 Aug; 12(1):140. PubMed ID: 28814322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points.
    Wason JM; Mander AP; Eisen TG
    Eur J Cancer; 2011 May; 47(7):983-9. PubMed ID: 21239164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
    King TE; Albera C; Bradford WZ; Costabel U; du Bois RM; Leff JA; Nathan SD; Sahn SA; Valeyre D; Noble PW
    Am J Respir Crit Care Med; 2014 Apr; 189(7):825-31. PubMed ID: 24476390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival trial design and monitoring using historical controls.
    Wu J; Xiong X
    Pharm Stat; 2016 Sep; 15(5):405-11. PubMed ID: 27307025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample size calculation for stepped wedge and other longitudinal cluster randomised trials.
    Hooper R; Teerenstra S; de Hoop E; Eldridge S
    Stat Med; 2016 Nov; 35(26):4718-4728. PubMed ID: 27350420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal response-adaptive randomized designs for multi-armed survival trials.
    Sverdlov O; Tymofyeyev Y; Wong WK
    Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.